SPONSOR
LEO Pharma
Total Trials
2
Recruiting
2
Phases
Phase 2, Phase 3
LEO Pharma is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Palmoplantar Pustulosis, Atopic Dermatitis.
The trial portfolio spans Phase 2, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — LEO Pharma
How many clinical trials has LEO Pharma sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by LEO Pharma, of which 2 are actively recruiting participants. These trials cover conditions including Palmoplantar Pustulosis, Atopic Dermatitis. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does LEO Pharma research focus on?
LEO Pharma clinical trials span Palmoplantar Pustulosis, Atopic Dermatitis. The research pipeline includes Phase 2, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a LEO Pharma clinical trial?
To participate in a LEO Pharma trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all LEO Pharma trials with current recruitment status updated daily.
Clinical Trials by LEO Pharma
NCT07013201 Phase 2
Recruiting
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
Palmoplantar Pustulosis
NCT06311682 Phase 3
Recruiting
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
Atopic Dermatitis
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology